Hospital Corporation of China (3869) Fundamentals 2026 — P/E 3.0x, Revenue Analysis | SniperIQ
Hospital Corporation of China (3869) is a CN-listed Healthcare company in Medical - Care Facilities with a market capitalization of HK$464M, trading at HK
Hospital Corporation of China (3869) has a market capitalization of approximately HK$464M, trading at HK
Hospital Corporation of China's trailing twelve-month P/E ratio is 3.0x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Hospital Corporation of China runs a net profit margin of 9.3%, a gross margin of 18.2%, and an operating margin of 8.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Hospital Corporation of China reported revenue of ¥1.5B for fiscal year 2025, with net income of ¥136M and earnings per share (EPS) of 0.97. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Hospital Corporation of China does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Hospital Corporation of China carries a debt-to-equity ratio of 2.10x and a current ratio of 1.62x, with a market beta of -0.31. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hospital Corporation of China (3869) the key facts are: market cap HK$464M, P/E 3.0x, revenue ¥1.5B, 52-week range 2.9-7.55. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Get Hospital Corporation of China's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.